Results 61 to 70 of about 264,642 (338)

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Cell Death and Disease, 2022
Immune checkpoint molecule programmed death-ligand 1 (PD-L1) is overexpressed in cancer cells and imparts resistance to cancer therapy. Although membrane PD-L1 has been targeted for cancer immune therapy, nuclear PD-L1 was reported to confer cancer ...
Je-Jung Lee, So Young Kim, Songhee H. Kim, Seoyeon Choi, Bin Lee, Jeon-Soo Shin   +5 more
doaj   +1 more source

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. [PDF]

, 2017
BACKGROUND: The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators to implement novel clinical trials which combine immunotherapy with different treatment modalities. Moreover is also important to investigate
Anniciello, Anna Maria, Ascierto, Paolo Antonio, Botti, Gerardo, Cantile, Monica, Caracò, Corrado, Cerrone, Margherita, Cirino, Giuseppe, Colombino, Maria, D’Alterio, Crescenzo, Fratangelo, Federica, Ianaro, Angela, Liguori, Giuseppina, Palmieri, Giuseppe, Pepe, Stefano, Sabbatino, Francesco, Scala, Stefania, Scognamiglio, Giosuè, Trimarco, Chiara   +17 more
core   +2 more sources

Deubiquitination and Stabilization of PD-L1 by CSN5 [PDF]

Cancer Cell, 2016
Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified tumor necrosis factor alpha (TNF-α) as a major factor triggering cancer cell immunosuppression against T cell surveillance via stabilization of programmed cell death-ligand 1 (
Aysegul A. Sahin, Chia Wei Li, Shih Shin Chang, Shih Shin Chang, Weiya Xia, Yi Hsin Hsu, Yun Wu, Wan Chi Lin, Mien Chie Hung, Yan Wang, Chung-Hsuan Chen, Li Chuan Chan, Wei Chao Chang, Gabriel N. Hortobagyi, Taewan Kim, Dihua Yu, Dihua Yu, Hirohito Yamaguchi, Yi Yang, Jong Ho Cha, Jennifer L. Hsu, Jung Mao Hsu, Seung Oe Lim, Qingqing Ding   +23 more
openaire   +3 more sources

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. [PDF]

, 2019
PD-L1 on the surface of tumor cells binds its receptor PD-1 on effector T cells, thereby suppressing their activity. Antibody blockade of PD-L1 can activate an anti-tumor immune response leading to durable remissions in a subset of cancer patients ...
Belair, Cassandra D, Blelloch, Robert, Chang, Anthony, Chu, Brandon, Fong, Lawrence, Fu, Qi, Hu, Tianyi, Lang, Ursula E, Montabana, Elizabeth, Pai, Chien-Chun, Poggio, Mauro   +10 more
core  

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors [PDF]

, 2020
Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL ...
Chen, Liang, Chen, Zhipeng, Coleman, James, Ding, Ke, Dong, Changjiang, Fan, Zhenzhen, Gao, Song, He, Jingjing, Huang, Junqi, Li, Nan, Liu, Lu, Tian, Yahui, Xu, Chenqi, Zhang, Zhimin, Zhou, Penghui, Zhou, Qian   +15 more
core   +1 more source

Standardization of PD-L1 immunohistochemistry [PDF]

Modern Pathology, 2022
Sandra Martinez-Morilla, Myrto Moutafi, David L. Rimm   +2 more
openaire   +3 more sources

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

DRG2 as a Biomarker to Enhance the Predictive Efficacy of PD-L1 Immunohistochemistry Assays

Biomedicines
PD-L1 immunohistochemistry (IHC) assays are used as a companion diagnostic for immunotherapy with immune checkpoint inhibitors (ICIs). However, despite the association between PD-L1 expression and clinical benefit from ICIs, the PD-L1 IHC assay is not ...
Muralidharan Mani, Seong Hee Choi, Hyuk Nam Kwon, Jeong Woo Park   +3 more
doaj   +1 more source